FROGENT: An End-to-End Full-process Drug Design Multi-Agent System

Ali NematiMar 325 sec read18 views

FROGENT is a new multi-agent system designed for full-process drug discovery that integrates large language models to automate and unify various stages of drug design, including target identification and molecule generation. This system significantly enhances efficiency and accuracy in drug development by reducing manual intervention, showcasing the potential of AI-driven tools in pharmaceutical research.

Read the full article at arXiv cs.AI (Artificial Intelligence)

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

Heatwaves driving recent 'surge' in compound drought and heat extremes

A recent study indicates that heatwaves are driving a surge in compound drought and heat extremes globally, particularly after global average temperat...A recent study indicates that heatwaves are driving a surge in compound drought and heat extremes globally, particularly after global average temperatures surpassed 14.3°C around the year 2000. The research highlights an intensification of land-atmos...

Ali Nemati

Biotech & PharmaFeb 2527 sec read

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic port...GlaxoSmithKline (GSK) acquired 35Pharma for $950 million to gain access to their pulmonary hypertension drug program, expanding GSK's therapeutic portfolio. This move is significant as it enhances GSK’s presence in specialized pharmaceutical markets ...

Ali Nemati

Biotech & PharmaFeb 2425 sec read

Abcuro drug fails muscle weakness trial, development to continue

Abcuro's experimental drug missed its primary and key secondary endpoints in a Phase 2b/3 trial for treating a rare autoimmune condition without FDA-a...Abcuro's experimental drug missed its primary and key secondary endpoints in a Phase 2b/3 trial for treating a rare autoimmune condition without FDA-approved therapies. Despite the setback, Abcuro plans to continue development, highlighting the persi...

Ali Nemati

Biotech & PharmaFeb 2431 sec read

Immedica wins accelerated approval for once-rejected rare disease drug

Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG...Swedish biotech Immedica received FDA accelerated approval for a drug addressing elevated plasma arginine levels in patients with the rare disease ARG1-D, marking a significant breakthrough after initial rejection. This approval offers new hope and t...

Ali Nemati

Biotech & PharmaFeb 2428 sec read

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma

Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior ...Budapest-based biotech company Turbine secured $25 million in Series B funding to advance its 'Virtual Lab' technology, which simulates cell behavior using AI models, aiming to revolutionize pharmaceutical research processes. This investment undersco...

Ali Nemati

FROGENT: An End-to-End Full-process Drug Design Multi-Agent System

Related Articles

Heatwaves driving recent 'surge' in compound drought and heat extremes

GSK to buy pulmonary hypertension biotech 35Pharma for $950M

Abcuro drug fails muscle weakness trial, development to continue

Immedica wins accelerated approval for once-rejected rare disease drug

AI biotech Turbine raises $25M Series B to sell 'Virtual Lab' to pharma